Eficacia y seguridad del interferón pegilado, asociado a la criocirugía en el tratamiento del condiloma acuminado

Abstract

BackgroundThe continuous recurrences of condylomata acuminata makes it necessary to constantly search for therapeutic alternatives. Patients and methodTo evaluate the therapeutic efficacy and safety of pegylated interferon (IFN p) adjuvant to cryosurgery, an open clinical trial was conducted in condylomata acuminata in 30 patients from the «Hermanos Ameijeiras» hospital, who were randomized to receive 6 weeks (group I) subcutaneous recombinant human interferon alfa 2b (IFN), 3 times per week + biweekly cryosurgery or (group II) subcutaneous IFN p, 1 time per week + biweekly cryosurgery. The main variable was the percentage of recurrence at one year of follow-up. There was also a rigorous control of adverse events. ResultsAt the end of the treatment 12/15 (80%) patients in group I and group II 14/15 (93,3%) were without injuries (p < 0.32). During follow-up, none of the patients who received IFN p + cryosurgery had recurrences; while 2/12 (16.7%) of the patients who received IFN + cryosurgery recurred (p < 0.672). Adverse events were significantly more frequent in group I (fever 13/15, headache 7/15, chills 3/15, and myalgia 2/15) (p < 0.003). ConclusionPegylated interferon with a weekly frequency of administration achieves superior therapeutic effects, a lower percentage of recurrences and adverse reactions than the administration of recombinant human IFN alpha 2b 3 times a week.